Opinion

Wafik S. El-Deiry: WIN Consortium in cancer personalized medicine MTB had well over 30 participants

Photo taken from: Wafik S. El-Deiry/LinkedIn

Mar 26, 2024, 00:22

Wafik S. El-Deiry: WIN Consortium in cancer personalized medicine MTB had well over 30 participants

Wafik S. El-Deiry shared on LinkedIn:

“Today’s WIN Consortium in cancer personalized medicine MTB had well over 30 participants from the US, Canada, Spain, Australia and Abu Dhabi. We had world experts on molecular drivers such as MDM2, EGFR, MET, RET as well as innovative immunotherapy combinations and ADC and bispecific Ab clinical trials. There were terrific discussions regarding considerations for SOC, clinical trials or rational combinations of agents based on drivers and resistance mechanisms. I certainly learned a lot and appreciate the input of our amazing colleagues”

Source: Wafik S. El-Deiry/LinkedIn

Wafik El-Deiry, MD, PhD, FACP, FRSM, an American Cancer Society Research Professor, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. This has been the most highly cited original work published in Cell. He discovered TRAIL receptor DR5 as a p53 target, and ONC201/TIC10 as a TRAIL pathway, integrated stress response inducer, and cancer therapeutic with efficacy in diffuse midline glioma and other tumors. He was named one of America’s Top Oncologists by the Consumer Res Council of America in 2008 and 2009. He is a practicing physician-scientist specializing in colorectal cancer treatment.